Immunovant, Inc. · NASDAQ:IMVT

Immunovant — Stifel 2021 Virtual Healthcare Conference

9 slides from Immunovant's conference presentation, Nov 17, 2021

  1. Slide 1: Stifel 2021 Virtual Healthcare Conference Investor Presentation

    Stifel 2021 Virtual Healthcare Conference Investor Presentation November 17, 2021 For Investor Audiences Only Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Forward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “expect,” “plan,” “anticipa

  3. Slide 3: Rethinking possibilities in autoimmune disease

    Rethinking possibilities in autoimmune disease 3 Love Trailblazing All Voices Bolder Faster Our vision: Normal lives for people with autoimmune diseases For Investor Audiences Only

  4. Slide 4: Anti-FcRn Market: Potential therapeutic benefit across wide range of indications

    4 Anti-FcRn Market: Potential therapeutic benefit across wide range of indications Fifteen indications announced by at least one anti-FcRn program ENDOCRINOLOGY Thyroid eye disease RHEUMATOLOGY Primary Sjögrens Syndrome Lupus Nephritis Systemic lupus erythematosus Rheumatoid arthritis DERMATOLOGY Bu

  5. Slide 5: Broad approach to understanding patient insights for Myasthenia Gravis (MG)

    5 In-depth Interviews Patient Advisory Council Digital Community Insights Broad approach to understanding patient insights for Myasthenia Gravis (MG) 5 Multi-pronged methodology Online Survey For Investor Audiences Only

  6. Slide 6: People with MG recognize limitations of current therapies, which keep them from living normal lives

    People with MG recognize limitations of current therapies, which keep them from living their normal lives Historical standards of care have important limitations Episodic or cyclical treatment – especially steroids and IvIg Prolonged time to onset for other immunosuppressants Potential trade-offs to

  7. Slide 7: Nearly 80% of people with MG reported moderate or major lifestyle modifications

    7 Nearly 80% of people with MG (on treatment) reported moderate or major lifestyle modifications 7 Source: MG Patient Survey (n=50). Q: What is the extent of lifestyle modifications you make around your myasthenia gravis? Slight lifestyle modifications Major lifestyle modifications Moderate lifestyl

  8. Slide 8: Chronic dosing preferred by MG patients surveyed

    8 Chronic Dosing: “I want to stay on my MG treatment, even when my symptoms are under control, so that I can maintain a response and avoid potential symptom flares” "It's easier to schedule life around something so consistent" 94% of MG patients surveyed preferred a chronic versus intermittent dosin

  9. Slide 9: Batoclimab's differentiated attributes provide a unique opportunity to address unmet needs

    Batoclimab’s (IMVT-1401) differentiated attributes provide a unique opportunity to address patients’ unmet needs 9 Subcutaneous route of administration: Designed and developed for simple subcutaneous injection to provide human-centric, give and go dosing experience Significant impact on quality of l

Immunovant — Stifel 2021 Virtual Healthcare Conference on 6ix